Remove Diagnostic Remove Disease Remove Radiopharmaceuticals
article thumbnail

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

AuntMinnie

However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care.

article thumbnail

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Imaging Technology

The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment. We focused on diagnostic accuracy, patient tolerance and convenience. milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.

article thumbnail

Radiopharmaceutical Diagnostics and Imaging Technologies

Open Medscience

Exploring the evolving role of radiopharmaceutical diagnostics in enhancing disease detection and personalising treatment in modern medicine. The post Radiopharmaceutical Diagnostics and Imaging Technologies appeared first on Open Medscience.

article thumbnail

The Transformative Power of Radiopharmaceuticals in Diagnostics

Open Medscience

Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.

article thumbnail

Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

Imaging Technology

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

article thumbnail

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Imaging Technology

and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.

article thumbnail

CMS proposes new coverage for PET imaging agents

AuntMinnie

Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).